Detection of MCM5 containing cells in urine has been shown to be indicative for the presence of a bladder tumour in primary diagnosis. The objective of this study was to evaluate diagnostic performance of ADXBLADDER in patients undergoing cystoscopic surveillance in Non Muscle Invasive Bladder Cancer (NMIBC) follow-up.
A multicentric prospective blinded study was carried out at 21 European centres in patients undergoing cystoscopy for NMIBC surveillance, diagnosed in the preceding 2 years. Urine was collected from all eligible patients and ADXBLADDER-MCM5 test was performed. Performance characteristics were calculated by comparing MCM5 results to the outcome of cystoscopy plus pathological assessment.
Of 1431 eligible patients enrolled, 127 were diagnosed with a bladder cancer recurrence. The overall sensitivity for the ADXBLADDER MCM5 test in detecting bladder cancer recurrence was 44.9% (95% CI 36.1-54%) with a 75.6% sensitivity for non pTaLG tumours (95% CI 59.7-87.6%). Specificity was 71.1% (95% CI 68.5-73.5%). The overall negative predictive value was 93% (95% CI 91.2-94.5%) however ADXBLADDER was able to rule out the presence of a non-pTaLG recurrent tumour with a NPV of 99.0% (95% CI 98.2-99.5%). No statistically significant differences in the performance of ADXBLADDER were observed as a result of age or sex.
This large blinded prospective study demonstrates that in the follow-up of NMIBC patients ADXBLADDER is able to exclude the presence of the most aggressive tumours with a NPV of 99%. These results indicate that ADXBLADDER could be incorporated in the follow-up strategy of NMIBC.
The Journal of urology. 2020 Apr 21 [Epub ahead of print]
Morgan Roupret, Paolo Gontero, Stuart R C McCracken, Tim Dudderidge, Jacqueline Stockley, Ashleigh Kennedy, Oscar Rodriguez, Caroline Sieverink, Felicien Vanié, Marco Allasia, J Alfred Witjes, Marc Colombel, Richard Sylvester, Fabrizio Longo, Emanuele Montanari, Joan Palou
Sorbonne Université, GRC n°5, PREDICTIVE ONCO-URO, AP-HP, Urology department, Hôpital Pitié-Salpêtrière, Paris, France., Ospedale Molinette, Dept. of Urology, Turin, Italy., Sunderland Royal Hospital, Dept. of Urology, Sunderland, United Kingdom., University Hospital Southampton, Dept. of Urology, Southampton, United Kingdom., Arquer Diagnostics, R&D, Sunderland, United Kingdom., Fundacio Puigvert, Dept of Urology, Barcelona, Spain., Radboud University Medical Centre, Dept. of Urology, Nijmegen, The Netherlands., Hôpital Edouard Herriot, Dept. of Urology, Lyon, France., EAU Non-muscle Invasive Bladder Cancer Guidelines Panel, EAU Guidelines Office, Brussels, Belgium., Universita' Policlinico Milano, Dept. of Urology, Milan, Italy.